Answers are grounded in this paper and cite their sources.
Rituximab is well tolerated among young people and is associated with few serious adverse events, but infections are common, corresponding to a prolonged period of B cell count recovery often lasting for longer than a year. Further examination of strategies to prevent infections following rituximab should be pursued.
No takes yet. Share an insight, caveat, or question.
McAtee et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: